

Anne Bergeron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8213267/publications.pdf>

Version: 2024-02-01

80
papers

4,496
citations

109137

35
h-index

102304

66
g-index

81
all docs

81
docs citations

81
times ranked

5210
citing authors

#	ARTICLE	IF	CITATIONS
1	Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 311-318.	0.2	2
2	Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 550-556.e2.	1.5	25
3	Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. <i>ERJ Open Research</i> , 2022, 8, 00185-2022.	1.1	14
4	Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100709.	0.5	5
5	Prospective comparison of (1,3)-beta-D-glucan detection using colorimetric and turbidimetric assays for diagnosing invasive fungal disease. <i>Medical Mycology</i> , 2021, 59, 882-889.	0.3	8
6	Profiles and outcomes in patients with COVID-19 admitted to wards of a French oncohematological hospital: A clustering approach. <i>PLoS ONE</i> , 2021, 16, e0250569.	1.1	3
7	Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2021, 194, 393-402.	1.2	22
8	Tuberculosis in allogeneic haematopoietic stem cell transplantation: so many unresolved questions!. <i>Bone Marrow Transplantation</i> , 2021, 56, 2050-2051.	1.3	0
9	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1549-1562.	2.0	3
10	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. <i>Blood Cancer Journal</i> , 2021, 11, 129.	2.8	0
11	Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 3032-3041.	1.3	5
12	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
13	Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 982-986.	1.3	25
14	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 392-400.	2.0	23
15	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2020, 71, 2787-2795.	2.9	44
16	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	2.9	53
17	Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2115-2120.	2.0	4
18	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020, 56, 2000279.	3.1	28

#	ARTICLE	IF	CITATIONS
19	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study. <i>Open Forum Infectious Diseases</i> , 2020, 7, S795-S796.	0.4	0
20	Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case series. <i>American Journal of Hematology</i> , 2019, 94, 1214-1226.	2.0	8
21	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). <i>Leukemia</i> , 2019, 33, 844-862.	3.3	131
22	Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 105-119.	1.0	34
23	Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. <i>European Respiratory Journal</i> , 2018, 51, 1702617.	3.1	71
24	Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation. <i>Clinical Lung Cancer</i> , 2018, 19, e57-e61.	1.1	5
25	Management of ITK pulmonary and pleural adverse effects: Fi-LMC guidelines. <i>Hematologie</i> , 2018, 24, 134-144.	0.0	0
26	Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. <i>Annals of Hematology</i> , 2018, 97, 541-542.	0.8	0
27	Lung histopathology of non-infectious pulmonary complications after allogeneic haematopoietic stem cell transplantation. <i>Histopathology</i> , 2018, 73, 832-842.	1.6	28
28	Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinics in Chest Medicine</i> , 2017, 38, 249-262.	0.8	35
29	Bosutinib-related pneumonitis. <i>European Respiratory Journal</i> , 2017, 50, 1700930.	3.1	5
30	Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinics in Chest Medicine</i> , 2017, 38, 607-621.	0.8	48
31	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017, 50, 1700217.	3.1	89
32	Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 557.	3.8	92
33	Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>JAMA Dermatology</i> , 2017, 153, 184.	2.0	17
34	Azithromycin and Survival After Hematopoietic Stem Cell Transplant—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2492.	3.8	0
35	Circulating <i>Aspergillus fumigatus</i> DNA Is Quantitatively Correlated to Galactomannan in Serum. <i>Frontiers in Microbiology</i> , 2017, 8, 2040.	1.5	21
36	Azole Resistance of <i>Aspergillus fumigatus</i> in Immunocompromised Patients with Invasive Aspergillosis. <i>Emerging Infectious Diseases</i> , 2016, 22, 157-158.	2.0	22

#	ARTICLE	IF	CITATIONS
37	Cystic Pulmonary Myxoid Liposarcoma Mimicking Endobronchial Blood Clot. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2016, 23, 152-154.	0.8	0
38	New therapeutic strategies for invasive aspergillosis in the era of azole resistance: how should the prevalence of azole resistance be defined?: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2075-2078.	1.3	14
39	Reply to "Early Lung Computed Tomography Scan after Allogeneic Hematopoietic Stem Cell Transplantation". <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1910.	2.0	0
40	Evidence of Th1, Th17 and Th17 cells in psoriasiform chronic graft-versus-host disease. <i>Experimental Dermatology</i> , 2016, 25, 64-65.	1.4	10
41	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. <i>Haematologica</i> , 2016, 101, e312-e315.	1.7	9
42	Early Lung Computed Tomography Scan after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1511-1516.	2.0	4
43	Idelalisib-related pneumonitis. <i>European Respiratory Journal</i> , 2016, 47, 1280-1283.	3.1	29
44	CT Imaging Assessment of Response to Treatment in Chronic Pulmonary Aspergillosis. <i>Chest</i> , 2016, 150, 139-147.	0.4	61
45	New Short Tandem Repeat-Based Molecular Typing Method for <i>Pneumocystis jirovecii</i> Reveals Intrahospital Transmission between Patients from Different Wards. <i>PLoS ONE</i> , 2015, 10, e0125763.	1.1	37
46	Budesonide/Formoterol for Bronchiolitis Obliterans after Hematopoietic Stem Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1242-1249.	2.5	93
47	CD24 ^{hi} CD27 ⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 1830-1839.	0.6	144
48	Phenotyping chronic pulmonary aspergillosis by cluster analysis. <i>European Respiratory Journal</i> , 2015, 46, 1509-1512.	3.1	11
49	Pulmonary Manifestations of Hematological Malignancies: Focus on Pulmonary Chronic Graft-Versus Host Disease. , 2015, , 517-527.		3
50	Human metapneumovirus pneumonia in patients with hematological malignancies. <i>Journal of Clinical Virology</i> , 2014, 61, 593-596.	1.6	28
51	Obliterative Bronchiolitis. <i>New England Journal of Medicine</i> , 2014, 370, 1820-1828.	13.9	253
52	Viral Respiratory Infections Diagnosed by Multiplex PCR after Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Incidence and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1238-1241.	2.0	34
53	Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. <i>Respiratory Medicine</i> , 2014, 108, 1525-1533.	1.3	50
54	Use and Limits of (1-3)- β -D-Glucan Assay (Fungitell), Compared to Galactomannan Determination (<i>Platelia Aspergillus</i>), for Diagnosis of Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2328-2333.	1.8	100

#	ARTICLE	IF	CITATIONS
55	Response Assessment in Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2012, 55, 475-476.	2.9	1
56	Cladribine Is Effective against Cystic Pulmonary Langerhans Cell Histiocytosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 930-932.	2.5	69
57	Prospective Evaluation of Clinical and Biological Markers To Predict the Outcome of Invasive Pulmonary Aspergillosis in Hematological Patients. <i>Journal of Clinical Microbiology</i> , 2012, 50, 823-830.	1.8	59
58	Persistent poor long-term prognosis of allogeneic hematopoietic stem cell transplant recipients surviving invasive aspergillosis. <i>Haematologica</i> , 2012, 97, 1357-1363.	1.7	17
59	The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. <i>Blood</i> , 2012, 119, 1831-1837.	0.6	124
60	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. <i>Circulation</i> , 2012, 125, 2128-2137.	1.6	548
61	Active Chronic Sarcoidosis is Characterized by Increased Transitional Blood B Cells, Increased IL-10-Producing Regulatory B Cells and High BAFF Levels. <i>PLoS ONE</i> , 2012, 7, e43588.	1.1	78
62	Severe chronic bronchiolitis as the presenting feature of primary Sjögren's syndrome. <i>Respiratory Medicine</i> , 2011, 105, 130-136.	1.3	40
63	The Spectrum of Lung Involvement in Collagen Vascular-Like Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Medicine (United States)</i> , 2011, 90, 146-157.	0.4	21
64	Contribution of Galactomannan Antigen Detection in BAL to the Diagnosis of Invasive Pulmonary Aspergillosis in Patients With Hematologic Malignancies. <i>Chest</i> , 2010, 137, 410-415.	0.4	76
65	Polyomaviruses KI and WU in Immunocompromised Patients with Respiratory Disease. <i>Emerging Infectious Diseases</i> , 2009, 15, 107-109.	2.0	65
66	Polymerase Chain Reaction for Diagnosing Pneumocystis Pneumonia in Non-HIV Immunocompromised Patients With Pulmonary Infiltrates. <i>Chest</i> , 2009, 135, 655-661.	0.4	160
67	A new pattern of cytosine arabinoside-induced lung toxicity. <i>British Journal of Haematology</i> , 2009, 147, 771-774.	1.2	19
68	Screening for tuberculosis before TNF α antagonist initiation: Are current methods good enough?. <i>Joint Bone Spine</i> , 2008, 75, 112-115.	0.8	3
69	Dasatinib-induced lupus. <i>Lancet, The</i> , 2008, 372, 713-714.	6.3	20
70	Treatment of Chronic Pulmonary Aspergillosis by Voriconazole in Nonimmunocompromised Patients. <i>Chest</i> , 2007, 131, 1435-1441.	0.4	159
71	Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 814-818.	2.5	189
72	Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2007, 45, 1019-1024.	2.9	94

#	ARTICLE	IF	CITATIONS
73	Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. <i>Haematologica</i> , 2007, 92, 1254-1257.	1.7	118
74	Clinical Picture of <i>Pneumocystis jiroveci</i> Pneumonia in Cancer Patients. <i>Chest</i> , 2007, 132, 1305-1310.	0.4	156
75	Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 551-554.	1.1	74
76	Primary Epstein-Barr Virus Infection with Pneumonia Transmitted by Allogeneic Bone Marrow after Transplantation. <i>Clinical Infectious Diseases</i> , 2006, 43, 892-895.	2.9	16
77	Breakthrough Disseminated <i>Aspergillus ustus</i> Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole or Caspofungin Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4902-4904.	1.8	83
78	The Prognosis of Acute Respiratory Failure in Critically Ill Cancer Patients. <i>Medicine (United States)</i> , 2004, 83, 360-370.	0.4	277
79	Is High-Resolution Computed Tomography a Reliable Tool to Predict the Histopathological Activity of Pulmonary Langerhans Cell Histiocytosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 264-270.	2.5	68
80	Relapsing Nodular Lesions in the Course of Adult Pulmonary Langerhans Cell Histiocytosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 2007-2010.	2.5	55